Profile of Predictive Factors of Response to Therapy in Patients with Diffuse Large B-cell Lymphoma in dr Soetomo General Teaching Hospital Surabaya
Despite the use of rituximab as a substantial treatment for Diffuse Large B-Cell Lymphoma (DLBCL), the survival rate remains low due to high incidences of relapse. Several predictive factors for relapse have been investigated however, still expensive and not applicable. Lymphocytemonocyte ratio (LMR...
Saved in:
Similar Items
-
CHOP and R-CHOP Therapeutic Responses in Non-HODGKIN Lymphoma Patients in Dr. Soetomo General Hospital Surabaya
by: Rina Syarifah Salma, et al.
Published: (2018) -
Management strategy for an advanced head of pancreas carcinoma patient with obstructive jaundice
by: Putu Niken Ayu Amrita, et al.
Published: (2019) -
Impact of molecular response time achievement on survival of chronic phase chronic myelogenous leukemia patients treated by imatinib
by: Putu Niken Ayu Amrita, et al.
Published: (2020) -
Gene Mutation Profile in Chronic Myelogenous Leukemia BCR-ABL.
Positive Chronic Phase Patients Which not Response to lmatinib
Treatment in Dr. Soetomo Teaching Hospital Surabaya lndonesia
by: Ugroseno Yudho Bintoro, Siprianus
Published: (2014) -
PROFIL FAKTOR PREDIKTOR RESPONS TERAPI PASIEN DIFFUSE LARGE B-CELL LYMPHOMA DI RSUD DR SOETOMO SURABAYA Penelitian deskriptif observasional retrospektif Poli Onkologi Satu AtapDivisi Hemato Onkologi Medik Departemen Penyakit Dalam
RSUD Dr. Soetomo Surabaya
by: MOCHAMMAD DILLIAWAN, NIM011180225
Published: (2017)